Certara, Inc. (CERT) shares plummeted 5.77% in pre-market trading on Thursday following the release of its fourth-quarter financial results and full-year 2026 guidance.

The biosimulation software company reported adjusted earnings per share of $0.09 for Q4 2025, missing the analyst consensus estimate of $0.11. Furthermore, the company posted a net loss of $5.9 million for the quarter, a significant 190% decline compared to a net income of $6.6 million in the same period last year.

Investor sentiment was further dampened by the company's outlook. Certara provided full-year 2026 guidance, expecting revenue growth of 0% to 4% and adjusted diluted earnings per share in the range of $0.44 to $0.48, which appears to be below the consensus estimate of $0.55. This combination of an earnings miss, a swing to a net loss, and conservative forward guidance is driving the sharp pre-market sell-off.